<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00499135</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2009-00245</org_study_id>
    <secondary_id>NCI-2009-00245</secondary_id>
    <secondary_id>CDR0000552705</secondary_id>
    <secondary_id>H-2007-0039</secondary_id>
    <secondary_id>CO06902</secondary_id>
    <secondary_id>CO 06902</secondary_id>
    <secondary_id>7898</secondary_id>
    <secondary_id>P30CA014520</secondary_id>
    <secondary_id>U01CA062491</secondary_id>
    <nct_id>NCT00499135</nct_id>
  </id_info>
  <brief_title>Sunitinib Malate in Treating Patients With Unresectable or Metastatic Kidney Cancer or Other Advanced Solid Tumors</brief_title>
  <official_title>Pharmacodynamic Study of Sunitinib Malate in Patients With Renal Cell Cancer and Other Advanced Solid Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This phase I trial is studying the side effects and best way to give sunitinib malate in&#xD;
      treating patients with unresectable or metastatic kidney cancer or other advanced solid&#xD;
      tumors. Sunitinib malate may stop the growth of tumor cells by blocking blood flow to the&#xD;
      tumor and by blocking some of the enzymes needed for cell growth.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the pharmacodynamic change using functional imaging (3'-deoxy-3'-[18F]&#xD;
      fluorothymidine [FLT]-positron emission tomography [PET]/computed tomography [CT] scans) in&#xD;
      patients with unresectable or metastatic clear cell renal cell carcinoma or other advanced&#xD;
      solid malignancies treated with two different schedules of sunitinib malate.&#xD;
&#xD;
      II. Evaluate the objective response in patients treated with this drug.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Measure the change in plasma vascular endothelial growth factor (VEGF) levels and plasma&#xD;
      hypoxia-inducible factor (HIF)1-alpha levels as a potential mechanism for vascular&#xD;
      endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI) failure and rapid&#xD;
      tumor growth following VEGFR TKI withdrawal in these patients.&#xD;
&#xD;
      II. Correlate pharmacokinetics of this drug with response, unexpected toxicity, VEGF levels,&#xD;
      HIF1-alpha levels, and FLT-PET/CT scan changes.&#xD;
&#xD;
      OUTLINE: Patients are assigned to 1 of 2 different treatment schedules of sunitinib malate.&#xD;
&#xD;
      SCHEDULE A: Patients receive sunitinib malate orally (PO) once daily (QD) in weeks 1-4.&#xD;
      Treatment repeats every 6 weeks in the absence of disease progression or unacceptable&#xD;
      toxicity.&#xD;
&#xD;
      SCHEDULE B: Patients receive sunitinib malate PO QD in weeks 1, 2, 4, and 5. Treatment&#xD;
      repeats every 6 weeks in the absence of disease progression or unacceptable toxicity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 22, 2007</start_date>
  <completion_date type="Actual">May 14, 2014</completion_date>
  <primary_completion_date type="Actual">May 14, 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response</measure>
    <time_frame>Up to 3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma VEGF and HIF1-alpha levels</measure>
    <time_frame>Up to 3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Standard uptake value as measured by 3'-deoxy-3'-[18F] fluorothymidine (FLT)-PET/CT scans</measure>
    <time_frame>Up to 3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters (Cmax, Tmax, AUC, T1/2, and CL)</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Adult Solid Neoplasm</condition>
  <condition>Clear Cell Renal Cell Carcinoma</condition>
  <condition>Recurrent Renal Cell Carcinoma</condition>
  <condition>Stage III Renal Cell Cancer</condition>
  <condition>Stage IV Renal Cell Cancer</condition>
  <arm_group>
    <arm_group_label>Schedule A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive sunitinib malate PO QD in weeks 1-4. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Schedule B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive sunitinib malate PO QD in weeks 1, 2, 4, and 5. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Computed Tomography</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Schedule A</arm_group_label>
    <arm_group_label>Schedule B</arm_group_label>
    <other_name>CAT</other_name>
    <other_name>CAT Scan</other_name>
    <other_name>Computerized Axial Tomography</other_name>
    <other_name>computerized tomography</other_name>
    <other_name>CT</other_name>
    <other_name>CT SCAN</other_name>
    <other_name>tomography</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Fluorothymidine F-18</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Schedule A</arm_group_label>
    <arm_group_label>Schedule B</arm_group_label>
    <other_name>18F-FLT</other_name>
    <other_name>3'-deoxy-3'-(18F) fluorothymidine</other_name>
    <other_name>3'-deoxy-3'-[18F]fluorothymidine</other_name>
    <other_name>fluorothymidine F 18</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Schedule A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pharmacological Study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Schedule A</arm_group_label>
    <arm_group_label>Schedule B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Positron Emission Tomography</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Schedule A</arm_group_label>
    <arm_group_label>Schedule B</arm_group_label>
    <other_name>Medical Imaging, Positron Emission Tomography</other_name>
    <other_name>PET</other_name>
    <other_name>PET Scan</other_name>
    <other_name>positron emission tomography scan</other_name>
    <other_name>Positron-Emission Tomography</other_name>
    <other_name>proton magnetic resonance spectroscopic imaging</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sunitinib Malate</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Schedule A</arm_group_label>
    <arm_group_label>Schedule B</arm_group_label>
    <other_name>SU011248</other_name>
    <other_name>SU11248</other_name>
    <other_name>sunitinib</other_name>
    <other_name>Sutent</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must have histologically or cytologically confirmed renal cell cancer; or&#xD;
             other solid malignancy (excluding lymphoma) that is metastatic or unresectable and for&#xD;
             which no standard curative therapy exists&#xD;
&#xD;
               -  For the renal cell cancer subset, a component of clear cell histology is required&#xD;
&#xD;
          -  Measurable disease, defined as &gt;= 1 unidimensionally measurable lesion &gt;= 20 mm by&#xD;
             conventional techniques or &gt;= 10 mm by spiral CT scan&#xD;
&#xD;
          -  Life expectancy &gt; 12 weeks&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2&#xD;
&#xD;
          -  Leukocytes &gt;= 3,000/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &gt;= 1,500/mm^3&#xD;
&#xD;
          -  Platelet count &gt;= 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin &gt;= 9 g/dL&#xD;
&#xD;
          -  Serum calcium =&lt; 12.0 mg/dL&#xD;
&#xD;
          -  Total bilirubin normal&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) (serum glutamic oxalo-acetic transaminase [SGOT]) and&#xD;
             alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =&lt; 2.5&#xD;
             times upper limit of normal (ULN), unless subjects have liver metastases, in which&#xD;
             case both AST and ALT must be =&lt; 5 x ULN&#xD;
&#xD;
          -  Creatinine =&lt; 2 times ULN OR creatinine clearance &gt;= 40 mL/min for patients with&#xD;
             creatinine levels above 2 x institutional normal&#xD;
&#xD;
          -  All patients need to be willing to undergo planned pharmacodynamic assessments,&#xD;
             including serial PET imaging, plasma markers, and pharmacokinetic sampling&#xD;
&#xD;
          -  Women of childbearing potential and men must agree to use adequate contraception&#xD;
             (hormonal or barrier method of birth control; abstinence) prior to study entry and for&#xD;
             the duration of study participation&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent document&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have had chemotherapy, radiotherapy, experimental therapy or major&#xD;
             surgery within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the&#xD;
             study or those who have not recovered (to grade &lt; 1 or baseline) from clinically&#xD;
             significant adverse events due to agents administered more than 4 weeks earlier&#xD;
             (alopecia and fatigue excluded); clinical significance to be determined by&#xD;
             investigator&#xD;
&#xD;
          -  Patients may not be receiving any other investigational agents&#xD;
&#xD;
          -  No prior treatment with an anti-VEGF agent allowed&#xD;
&#xD;
          -  History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition to sunitinib malate&#xD;
&#xD;
          -  Patients with QTc prolongation (defined as a QTc interval greater than 500 msec) or&#xD;
             other significant electrocardiogram (ECG) abnormalities (per investigator discretion)&#xD;
             are excluded&#xD;
&#xD;
          -  Patients with poorly controlled hypertension (systolic blood pressure of 140 mm Hg or&#xD;
             higher or diastolic blood pressure of 90 mm Hg or higher) are ineligible&#xD;
&#xD;
          -  Patients with any condition (e.g., gastrointestinal tract disease resulting in an&#xD;
             inability to take oral medication or a requirement for IV alimentation, prior surgical&#xD;
             procedures affecting absorption, or active peptic ulcer disease) that impairs their&#xD;
             ability to swallow and retain sunitinib tablets are excluded&#xD;
&#xD;
          -  Patients with any of the following conditions are excluded:&#xD;
&#xD;
               -  Serious or nonhealing wound, ulcer, or bone fracture&#xD;
&#xD;
               -  Abdominal fistula, gastrointestinal (GI) perforation, or intra-abdominal abscess&#xD;
                  within the past 28 days&#xD;
&#xD;
               -  Cerebrovascular accident (CVA) or transient ischemic attack within 12 months&#xD;
                  prior to study entry&#xD;
&#xD;
               -  History of myocardial infarction, cardiac arrhythmia, stable/unstable angina,&#xD;
                  symptomatic congestive heart failure, or coronary/peripheral artery bypass graft&#xD;
                  or stenting within the past 12 months&#xD;
&#xD;
               -  History of pulmonary embolism within the past 12 months&#xD;
&#xD;
               -  Class III or IV heart failure as defined by the New York Heart Association (NYHA)&#xD;
                  functional classification system&#xD;
&#xD;
          -  Patients with a pre-existing thyroid abnormality who are unable to maintain thyroid&#xD;
             function in the normal range with medication are ineligible; patients with a history&#xD;
             of hypothyroidism are eligible provided they are currently euthyroid&#xD;
&#xD;
          -  Patients with known brain metastases&#xD;
&#xD;
          -  Patients with uncontrolled intercurrent illness including, but not limited to, ongoing&#xD;
             or active infections or psychiatric illness/social situations that would limit&#xD;
             compliance with study requirements are ineligible&#xD;
&#xD;
          -  Pregnant or breastfeeding&#xD;
&#xD;
          -  No concurrent therapeutic doses of coumarin-derivative anticoagulants, such as&#xD;
             warfarin; Concurrent doses =&lt; 2 mg/day allowed for prophylaxis of thrombosis,&#xD;
             Concurrent low molecular weight heparin allowed provided prothrombin time (PT)&#xD;
             international normalized ratio ( INR) =&lt; 1.5&#xD;
&#xD;
          -  No concurrent agents with proarrhythmic potential (terfenadine, quinidine,&#xD;
             procainamide, disopyramide, sotalol, probucol, bepridil, haloperidol, risperidone,&#xD;
             indapamide, and flecainide acetate)&#xD;
&#xD;
          -  Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral&#xD;
             therapy are ineligible&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Glenn Liu</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Wisconsin Hospital and Clinics</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <study_first_submitted>July 10, 2007</study_first_submitted>
  <study_first_submitted_qc>July 10, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2007</study_first_posted>
  <last_update_submitted>October 9, 2017</last_update_submitted>
  <last_update_submitted_qc>October 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alovudine</mesh_term>
    <mesh_term>Sunitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

